key: cord-0992850-vc1omxl8 authors: Conde-Agudelo, Agustin; Romero, Roberto title: SARS-COV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis date: 2021-07-21 journal: Am J Obstet Gynecol DOI: 10.1016/j.ajog.2021.07.009 sha: de0f6aa185b10ffdf37359e7a37fb1bf4e50d398 doc_id: 992850 cord_uid: vc1omxl8 OBJECTIVE To examine the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy and the risk of preeclampsia. DATA SOURCES MEDLINE, EMBASE, POPLINE, CINAHL, LILACS, and WHO COVID-19, Chinese, and preprint databases (all from December 1, 2019 to May 31, 2021). Google Scholar, bibliographies, and conference proceedings were also searched. STUDY ELIGIBILITY CRITERIA Observational studies that assessed the association between SARS-CoV-2 infection during pregnancy and preeclampsia and that reported unadjusted and/or adjusted risk estimates and 95% confidence intervals (CIs) or data to calculate them. STUDY APPRAISAL AND SYNTHESIS METHODS The primary outcome was preeclampsia. Secondary outcomes included preeclampsia with severe features, preeclampsia without severe features, eclampsia, and the hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Two reviewers independently reviewed studies for inclusion, assessed their risk of bias, and extracted data. Pooled unadjusted and adjusted odds ratios (ORs) with 95% CIs, and 95% prediction interval were calculated. Heterogeneity was quantified with the І 2 statistic, where І 2 ≥30% indicated substantial heterogeneity. Subgroup and sensitivity analyses were performed for testing the robustness of the overall findings. RESULTS Twenty-eight studies that included 790,954 pregnant women, among which 15,524 were diagnosed with SARS-CoV-2 infection, met the inclusion criteria. The meta-analysis of unadjusted ORs showed that the odds of developing preeclampsia were significantly higher among pregnant women with SARS-CoV-2 infection than among those without SARS-CoV-2 infection (7.0% vs 4.8%; pooled OR 1.62, 95% CI 1.45-1.82; P <0.00001; І 2=17%; 26 studies; 95% prediction interval of the OR, 1.28-2.05). The meta-analysis of adjusted ORs also showed that SARS-CoV-2 infection during pregnancy was associated with a significant increase in the odds of preeclampsia (pooled OR 1.58, 95% CI 1.39-1.80; P <0.0001; І 2=0%; 11 studies). There was a statistically significant increase in the odds of preeclampsia with severe features (OR 1.76, 95% CI 1.18-2.63; І 2=58%; 7 studies), eclampsia (OR 1.97, 95% CI 1.01-3.84; І 2=0%, 3 studies), and HELLP syndrome (OR 2.10, 95% CI 1.48-2.97; 1 study) among pregnant women with SARS-CoV-2 infection, as compared to those without the infection. Overall, the direction and magnitude of the effect of SARS-CoV-2 infection during pregnancy on preeclampsia was consistent across most pre-specified subgroup and sensitivity analyses. Both asymptomatic and symptomatic SARS-CoV-2 infections significantly increased the odds of preeclampsia although it was higher among patients with symptomatic illness (OR 2.11, 95% CI 1.59-2.81) than among those with asymptomatic illness (OR 1.59, 95% CI 1.21-2.10). CONCLUSIONS SARS-CoV-2 during pregnancy is associated with higher odds of preeclampsia. Preeclampsia, a multisystem syndrome that complicates about 5% of pregnancies, 158 is one of the leading causes of maternal mortality worldwide, accounting for 159 approximately 14% of all maternal deaths. 1, 2 In 2018, preeclampsia was 160 responsible for 5.3% of maternal deaths in the United States. 3 Preeclampsia is also 161 associated with an increased risk for maternal morbidity and perinatal morbidity 162 and mortality worldwide, mainly in low-and middle-income countries. [4] [5] [6] [7] [8] [9] [10] [11] [12] In Hence, we performed a systematic review whose primary aim was to compile and 207 critically assess the existing evidence on the relationship between SARS-CoV-2 208 infection during pregnancy and the risk of preeclampsia by using formal methods 209 for systematic reviews and meta-analytic techniques. Our search terms included a combination of keywords and text words related to 225 SARS-CoV-2 ("SARS-CoV-2", "COVID-19", "2019-nCoV", "nCov-2019", "SARS- 226 CoV-19", "coronavirus", "betacoronavirus", and "severe acute respiratory 227 syndrome"), preeclampsia ("preeclampsia", "eclampsia", "gestosis, EPH", 228 "pregnancy toxemia", "pregnancy-induced hypertension", "hypertensive disorders 229 of pregnancy", "gestational hypertension", "pregnancy-associated hypertension", 230 and "pregnancy hypertension") and pregnancy ("pregnancy", "gestation", and 231 "gravidity"). Google Scholar, proceedings of congresses on obstetrics, maternal-232 fetal medicine, pediatrics and neonatology, reference lists of identified studies, 233 previously published systematic reviews, and review articles were also searched. No language restrictions were applied. Study selection 237 We included observational studies that assessed the relationship between 238 SARS-CoV-2 infection during pregnancy and preeclampsia and reported 239 unadjusted and/or adjusted odds ratio (OR) or relative risk (RR) estimates and 240 95% confidence intervals (CIs) or data to calculate them. The exposed group a negative test result for RT-PCR or antigen in a sample 247 collected from the upper respiratory tract, or a negative antibody test result in 248 serum, or those who were pregnant and delivered before the pandemic. Given 249 that no routine diagnostic testing for SARS-CoV-2 infection was available at the 250 beginning of the pandemic, we included studies in which pregnant women were 251 assigned to exposed or unexposed groups based on the presence or absence 252 of clinical signs/symptoms and/or chest computerized tomography or radiograph 253 images. Studies were excluded from the review if they (1) were case series or 255 reports, editorials, comments, reviews, or letters without original data; (2) 3. Inclusion in the non-exposed cohort -"Low risk of bias": ≥90% of included 297 women had a negative RT-PCR or antigen test result or negative SARS-CoV-2 298 antibodies, or women were drawn from a historical control group who delivered 299 before the beginning of the COVID-19 pandemic; "high risk of bias": <90% of 300 included women had a negative RT-PCR or antigen test result, or negative SARS- If there was insufficient information available to make a judgment about these 314 domains, then they were scored as "unclear risk of bias". severe/critical disease). These data strongly suggest a dose-response effect. Temporality is considered fundamental when assessing the likelihood of a 547 causal relationship between an exposure and an outcome. 116, 117 Evidence that 548 participants were exposed before the occurrence of the outcome strengthens a 32 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 Study Inclusion in the exposed cohort Inclusion in the non-exposed cohort * The open circles indicate the observed studies, and the filled circles indicate the missing studies imputed by the "Trim and Fill" method. Global and regional estimates 767 of preeclampsia and eclampsia: a systematic review Global causes of maternal death: a WHO systematic 772 analysis Maternal mortality in the United States: changes in 775 coding, publication, and data release Clinical features of patients 1002 infected with 2019 novel coronavirus in Wuhan, China COVID-19 and pregnancy: An umbrella review of clinical presentation, 1007 vertical transmission, and maternal and perinatal outcomes Clinical 1011 manifestations, risk factors, and maternal and perinatal outcomes of 1012 coronavirus disease 2019 in pregnancy: living systematic review and meta-1013 analysis Update: characteristics of symptomatic women of reproductive age with 1017 laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United 1018 Are 1022 clinical outcomes worse for pregnant women at ≥20 weeks' gestation infected 1023 with coronavirus disease 2019? A multicenter case-control study with 1024 propensity score matching Public Health Agency of Sweden's 1027 Brief Report: Pregnant and postpartum women with severe acute respiratory 1028 syndrome coronavirus 2 infection in intensive care in Sweden Intensive care unit admissions for pregnant and 1032 nonpregnant women with coronavirus disease 2019 Arian 1036 SE, et al. Maternal death due to COVID-19 The risk of clinical 1040 complications and death among pregnant women with COVID-19 in the Cerner 1041 COVID-19 cohort: a retrospective analysis 1045 Pregnant women with severe or critical coronavirus disease Pregnant women with SARS-CoV-2 infection 1051 are at higher risk of death and pneumonia: propensity score matched analysis 1052 of a nationwide prospective cohort (COV19Mx) Disease severity, pregnancy outcomes, and maternal deaths 1057 among pregnant patients with severe acute respiratory syndrome coronavirus 2 1058 infection in Washington State Higher severe acute respiratory syndrome coronavirus 2 infection rate 1062 in pregnant patients The differences in 1065 clinical presentation, management, and prognosis of laboratory COVID-19 between pregnant and non-pregnant women: a systematic review 1067 and meta-analysis Young pregnant women are also at an increased risk of 1071 mortality and severe illness due to coronavirus disease 2019: analysis of the 1072 Mexican National Surveillance Program Adverse pregnancy outcomes among individuals with and 1077 without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a 1078 systematic review and meta-analysis The impact of COVID-19 on 1081 pregnancy outcomes: a systematic review and meta-analysis Meta-1085 analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group Gestational 1091 hypertension and preeclampsia The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & 1095 management recommendations for international practice Measuring inconsistency in 1099 meta-analyses A re-evaluation of random-effects 1102 meta-analysis Interpretation of random effects meta-1105 analyses Plea for routinely presenting 1108 prediction intervals in meta-analysis Bias in meta-analysis 1111 detected by a simple, graphical test Operating characteristics of a rank correlation test for 1114 publication bias Trim and fill: A simple funnel-plot-based method of testing 1117 and adjusting for publication bias in meta-analysis trim and fill" method of accounting for 1120 publication bias in meta-analysis Association of SARS-CoV-2 test status and pregnancy outcomes COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical 1128 transmission: a population-based cohort study in Wuhan, China SARS-CoV-2 in New York City: a prospective cohort study Coronavirus disease 2019 pregnancy outcomes in a racially and ethnically 1138 diverse population Pregnancy outcomes among women with and without severe acute 1142 respiratory syndrome coronavirus 2 infection Obstetric hemorrhage risk 1150 associated with novel COVID-19 diagnosis from a single-institution cohort in the 1151 United States Severe acute respiratory syndrome coronavirus 2 (SARS-1155 CoV-2) antibodies at delivery in women, partners, and newborns Maternal, 1159 fetal and neonatal outcomes of large series of SARS-CoV-2 positive 1160 pregnancies in peripartum period: A single-center prospective comparative 1161 study 1168 WA. COVID-19 and new hypertensive disease in pregnancy Miami mother-baby COVID collaborative: a prospective study linking circulating 1173 factors, placental findings and pregnancy complications 1177 Comparison of VEGF-A values between pregnant women with COVID-19 and 1178 Transplacental transmission of SARS-CoV-2 infection Visualization of severe acute respiratory syndrome coronavirus 2 invading the 1361 human placenta using electron microscopy SARS-CoV-2 infection of the placenta Detection of severe acute respiratory syndrome coronavirus 2 in placental and 1370 fetal membrane samples Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over 1374 TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-1375 fetal dyads A 1378 possible case of vertical transmission of severe acute respiratory syndrome 1379 coronavirus 2 (SARS-CoV-2) in a newborn with positive placental in situ 1380 hybridization of SARS-CoV-2 RNA Confirmatory evidence of the visualization of severe acute respiratory syndrome 1384 coronavirus 2 invading the human placenta using electron microscopy Trophoblast damage with acute and chronic intervillositis: disruption of the 1389 placental barrier by severe acute respiratory syndrome coronavirus 2 Maternal respiratory SARS-CoV-2 infection in pregnancy is 1394 associated with a robust inflammatory response at the maternal-fetal interface and intrauterine maternal-fetal severe acute respiratory syndrome coronavirus 2 1401 (SARS-CoV-2) transmission in live-born and stillborn infants SARS-CoV-2 1405 infects syncytiotrophoblast and activates inflammatory responses in the 1406 placenta CoV-2 colonization of maternal and fetal cells of the human placenta promotes 1410 alteration of local renin-angiotensin system Potential SARS-CoV-2 interactions with proteins involved in trophoblast 1414 functions -an in-silico study The risk of COVID-19 for pregnant women: evidences of molecular 1418 alterations associated with preeclampsia in SARS-CoV-2 infection The case of the misleading 1422 funnel plot Recommendations for examining and interpreting funnel plot asymmetry in 1426 meta-analyses of randomised controlled trials Funnel plots may 1429 show asymmetry in the absence of publication bias with continuous outcomes 1430 dependent on baseline risk: presentation of a new publication bias test The American College of Obstetricians and Gynecologists Society for Maternal-Fetal Medicine. Management Considerations for Pregnant 1439 Patients With COVID-19 Guidance for maternal 1445 medicine services in the coronavirus (COVID-19) pandemic. Available at ISUOG 1457 interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy 1458 and puerperium: information for healthcare professionals -an update Should we stop 1462 aspirin prophylaxis in pregnant women diagnosed with COVID-19 Effects of the COVID-19 pandemic on maternal and perinatal 1467 outcomes: a systematic review and meta-analysis Covid-19 pandemic on maternity services: A review of maternal and neonatal 1472 outcomes before, during and after the pandemic Risk for probable post-partum depression among women during 1477 the COVID-19 pandemic Increased rates of hypertensive 1480 disorders of pregnancy during the COVID-19 pandemic Impact of COVID-19 on obstetrical 1484 outcomes at a single academic medical center Pregnancy and birth 1488 outcomes after SARS-CoV-2 vaccination in pregnancy. medRxiv